1887
Preview this article:
Zoom in
Zoomout

Telavancin and daptomycin activity against meticillin-resistant strains after vancomycin-resistance selection , Page 1 of 1

| /docserver/preview/fulltext/jmm/62/7/1101_jmm060640-1.gif

There is no abstract available for this article.
Use the preview function to the left.

Loading

Article metrics loading...

/content/journal/jmm/10.1099/jmm.0.060640-0
2013-07-01
2020-08-13
Loading full text...

Full text loading...

/deliver/fulltext/jmm/62/7/1101.html?itemId=/content/journal/jmm/10.1099/jmm.0.060640-0&mimeType=html&fmt=ahah

References

  1. Cui L., Ma X., Sato K., Okuma K., Tenover F. C., Mamizuka E. M., Gemmell C. G., Kim M. N., Ploy M. C. et al. 2003; Cell wall thickening is a common feature of vancomycin resistance in Staphylococcus aureus. J Clin Microbiol 41:5–14 [CrossRef][PubMed]
    [Google Scholar]
  2. Cui L., Lian J. Q., Neoh H. M., Reyes E., Hiramatsu K. 2005; DNA microarray-based identification of genes associated with glycopeptide resistance in Staphylococcus aureus. Antimicrob Agents Chemother 49:3404–3413 [CrossRef][PubMed]
    [Google Scholar]
  3. Draghi D. C., Benton B. M., Krause K. M., Thornsberry C., Pillar C., Sahm D. F. 2008; Comparative surveillance study of telavancin activity against recently collected gram-positive clinical isolates from across the United States. Antimicrob Agents Chemother 52:2383–2388 [CrossRef][PubMed]
    [Google Scholar]
  4. Gander S., Kinnaird A., Finch R. 2005; Telavancin: in vitro activity against staphylococci in a biofilm model. J Antimicrob Chemother 56:337–343 [CrossRef][PubMed]
    [Google Scholar]
  5. Hobbs J. K., Miller K., O’Neill A. J., Chopra I. 2008; Consequences of daptomycin-mediated membrane damage in Staphylococcus aureus. J Antimicrob Chemother 62:1003–1008 [CrossRef][PubMed]
    [Google Scholar]
  6. Jones R. N. 2006; Microbiological features of vancomycin in the 21st century: minimum inhibitory concentration creep, bactericidal/static activity, and applied breakpoints to predict clinical outcomes or detect resistant strains. Clin Infect Dis 42:Suppl 1S13–S24 [CrossRef][PubMed]
    [Google Scholar]
  7. Jung D., Rozek A., Okon M., Hancock R. E. 2004; Structural transitions as determinants of the action of the calcium-dependent antibiotic daptomycin. Chem Biol 11:949–957 [CrossRef][PubMed]
    [Google Scholar]
  8. Kanafani Z. A. 2006; Telavancin: a new lipoglycopeptide with multiple mechanisms of action. Expert Rev Anti Infect Ther 4:743–749 [CrossRef][PubMed]
    [Google Scholar]
  9. Leuthner K. D., Cheung C. M., Rybak M. J. 2006; Comparative activity of the new lipoglycopeptide telavancin in the presence and absence of serum against 50 glycopeptide non-susceptible staphylococci and three vancomycin-resistant Staphylococcus aureus. J Antimicrob Chemother 58:338–343 [CrossRef][PubMed]
    [Google Scholar]
  10. Liu C., Bayer A., Cosgrove S. E., Daum R. S., Fridkin S. K., Gorwitz R. J., Kaplan S. L., Karchmer A. W., Levine D. P. et al. 2011; Clinical practice guidelines by the infectious diseases society of America for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children. Clin Infect Dis 52:e18–e55 [CrossRef][PubMed]
    [Google Scholar]
  11. Moubareck C., Meziane-Cherif D., Courvalin P., Périchon B. 2009; VanA-type Staphylococcus aureus strain VRSA-7 is partially dependent on vancomycin for growth. Antimicrob Agents Chemother 53:3657–3663 [CrossRef][PubMed]
    [Google Scholar]
  12. Neoh H. M., Hori S., Komatsu M., Oguri T., Takeuchi F., Cui L., Hiramatsu K. 2007; Impact of reduced vancomycin susceptibility on the therapeutic outcome of MRSA bloodstream infections. Ann Clin Microbiol Antimicrob 6:13 [CrossRef][PubMed]
    [Google Scholar]
  13. Pace J. L., Krause K., Johnston D., Debabov D., Wu T., Farrington L., Lane C., Higgins D. L., Christensen B. et al. 2003; In vitro activity of TD-6424 against Staphylococcus aureus. Antimicrob Agents Chemother 47:3602–3604 [CrossRef][PubMed]
    [Google Scholar]
  14. Peleg A. Y., Miyakis S., Ward D. V., Earl A. M., Rubio A., Cameron D. R., Pillai S., Moellering R. C. Jr, Eliopoulos G. M. 2012; Whole genome characterization of the mechanisms of daptomycin resistance in clinical and laboratory derived isolates of Staphylococcus aureus. PLoS ONE 7:e28316 [CrossRef][PubMed]
    [Google Scholar]
  15. Petrosillo N., Capone A., Di Bella S., Taglietti F. 2010; Management of antibiotic resistance in the intensive care unit setting. Expert Rev Anti Infect Ther 8:289–302 [CrossRef][PubMed]
    [Google Scholar]
  16. Sakoulas G., Moise-Broder P. A., Schentag J., Forrest A., Moellering R. C. Jr, Eliopoulos G. M. 2004; Relationship of MIC and bactericidal activity to efficacy of vancomycin for treatment of methicillin-resistant Staphylococcus aureus bacteremia. J Clin Microbiol 42:2398–2402 [CrossRef][PubMed]
    [Google Scholar]
  17. van Hal S. J., Paterson D. L., Gosbell I. B. 2011; Emergence of daptomycin resistance following vancomycin-unresponsive Staphylococcus aureus bacteraemia in a daptomycin-naïve patient–a review of the literature. Eur J Clin Microbiol Infect Dis 30:603–610 [CrossRef][PubMed]
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jmm/10.1099/jmm.0.060640-0
Loading
/content/journal/jmm/10.1099/jmm.0.060640-0
Loading

Data & Media loading...

Most cited this month Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error